Should PD-L1 Expression Be Used As A Biomarker For Immunotherapy?
Oncologists’ distrust of the PD-L1 biomarker was more evident at ASCO than ever. Regardless of what “marketing people” might want, immunotherapy demands more than a single biomarker, MD Anderson GU specialist Padmanee Sharma tells a packed audience on opening day. >>>Listen in to an audio clip of Genentech’s Ira Mellman discussing the company’s view.
You may also be interested in...
US FDA’s Information First Policy: PD-1 Bladder Cancer Alert Aligns With Complementary Diagnostics Perspective
Tecentriq and Keytruda's apparently lower efficacy in low PD-1/L1 patients in ongoing first-line trials prompts communication instead of restriction, underscoring FDA's emerging approach to precision medicine labeling.
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.